Phase 4 Atrial Fibrillation Trial, Recruiting NCT06528262 Sponsor: Yonsei University Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Phase 4 Atrial Fibrillation Trial, Recruiting

NCT06528262
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between the ages of 19 and under 85
  • People who are willing to give their consent to take part and are able to attend follow-up appointments during the study
  • People who have both atrial fibrillation (an irregular heartbeat) and heart failure, and who have either had a catheter ablation procedure for atrial fibrillation within the last three months, or have one scheduled

Who may not be able to join:

  • People who are under 19 or 85 years of age or older
  • People who have taken part in another clinical trial within the last three months
  • People who are expected to live less than one year
  • Women who are pregnant or breastfeeding
  • People who are currently being treated with a type of medication called an SGLT-2 inhibitor
  • People who have had three or more urinary or genital infections in the past year
  • People with poorly controlled high blood pressure (confirm with trial site for specific measurements)
  • People with very low blood pressure (confirm with trial site for specific measurements)
  • People who have had a serious heart or cardiovascular event within the last 12 weeks
  • People with severe heart valve disease or who have artificial heart valves
  • People with significantly reduced kidney function (confirm with trial site for specific measurements)
  • People with a medically confirmed liver condition affecting liver function
  • People with thyroid problems that are not well controlled
  • People who currently have cancer or are receiving cancer treatment, or who have had cancer within the last five years — though some people with certain low-risk cancers that were successfully treated may still be eligible (confirm with trial site)
  • People who have been taking high-dose steroid tablets (such as prednisolone at 10mg per day or more) continuously within the last month
  • People who have had an allergic reaction to any ingredient in the study drug, or who have a history of such a reaction
  • People with type 1 diabetes or a condition called diabetic ketoacidosis
  • People with a history of alcohol or substance misuse
  • Women who could become pregnant but are unwilling to use adequate contraception for the duration of the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
3 April 2025
Est. completion
31 May 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Difference in the recurrence rate of atrial fibrillation (AF) between the experimental group (enavogliflozin group) and the control group (placebo group) from 3 months to 1 year after catheter ablation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov